Open AccessComposite Lipid Emulsion for the Infant at Risk of Intestinal Failure–associated Liver Disease
Author(s) -
Silverman Jason A.,
Turner Justine M.,
Wales Paul W.
Publication year - 2020
Publication title -
journal of pediatric gastroenterology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 131
eISSN - 1536-4801
pISSN - 0277-2116
DOI - 10.1097/mpg.0000000000002794
Subject(s) - intestinal failure , medicine , parenteral nutrition , lipid emulsion , liver disease , fat emulsion , emulsion , intensive care medicine , liver failure , biochemistry , chemistry
Currently, in North America we are fortunate to have a number of available options for lipid emulsions to be used in the parenteral nutrition regimens for infants and children, including for long‐term parenteral nutrition given intestinal failure. Neonates and infants in particular are at risk for intestinal failure–associated liver disease (IFALD). The choice of parenteral lipid emulsion will influence the risk and severity of IFALD. The purpose of this review is to discuss the rationale for the composite lipid emulsion SMOFlipid that includes s oybean, m edium‐chain triglycerides, o live and f ish oils for IFALD, with focus on the Canadian practice and experience.